HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Atovaquone for the treatment of toxoplasma retinochoroiditis in immunocompetent patients.

AbstractOBJECTIVE:
To report the results of a phase I trial to evaluate the safety and efficacy of atovaquone for the treatment of ocular toxoplasmosis in immunocompetent patients.
DESIGN:
Open label, nonrandomized, prospective, clinical trial.
PARTICIPANTS:
Seventeen immunocompetent patients between the ages of 18 and 75 years with clinical and serologic evidence of ocular toxoplasmosis participated.
INTERVENTION:
Treatment of ocular toxoplasmosis with atovaquone tablets (750 mg four times a day) for 3 months. Prednisone (40 mg) tablets were added on day 3 of treatment and tapered as inflammation resolved.
MAIN OUTCOME MEASURES:
Clinical response and patient tolerance to atovaquone therapy for ocular toxoplasmosis.
RESULTS:
Average follow-up was 10 months. Most patients experienced no adverse treatment effects. When present, side effects were usually mild and included rash, pruritus, headache, and nausea. With the exception of one patient, who discontinued treatment at 6 weeks secondary to persistent epigastric discomfort, all patients completed the 12 weeks of therapy. All patients had a favorable response to treatment that began within 1 to 3 weeks. Visual acuity was stabilized or improved in all patients. Median initial visual acuity was 20/200 and median final visual acuity was 20/25. In general, atovaquone was well tolerated.
CONCLUSIONS:
Atovaquone is better tolerated than conventional antitoxoplasmosis therapy and appears to be at least as effective. Atovaquone is a promising alternative for the treatment of ocular toxoplasmosis in immunocompetent patients.
AuthorsP A Pearson, A R Piracha, H A Sen, G J Jaffe
JournalOphthalmology (Ophthalmology) Vol. 106 Issue 1 Pg. 148-53 (Jan 1999) ISSN: 0161-6420 [Print] United States
PMID9917796 (Publication Type: Case Reports, Clinical Trial, Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antiprotozoal Agents
  • Naphthoquinones
  • Atovaquone
Topics
  • Adolescent
  • Adult
  • Aged
  • Antiprotozoal Agents (adverse effects, therapeutic use)
  • Atovaquone
  • Chorioretinitis (drug therapy, parasitology, pathology)
  • Drug Evaluation
  • Female
  • Follow-Up Studies
  • Fundus Oculi
  • Humans
  • Immunocompetence
  • Middle Aged
  • Naphthoquinones (adverse effects, therapeutic use)
  • Prospective Studies
  • Safety
  • Toxoplasmosis, Ocular (drug therapy, parasitology, pathology)
  • Treatment Outcome
  • Visual Acuity

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: